DF/HCC SPORE in Prostate Cancer

本申请是丹娜-法伯/哈佛癌症中心前列腺癌项目（DF/HCC）前列腺癌卓越研究专业项目（SPORE）的修订再提交申请。自2002年以来，DF/HCC前列腺癌孢子已经资助了两个周期。DF/HCC由以下机构组成：丹娜-法伯癌症研究所；哈佛医学院；哈佛大学公共卫生学院；贝斯以色列女执事医疗中心；布里格姆妇女医院；马萨诸塞州总医院；以及波士顿儿童医院除了DF/HCC中的机构外，布罗德研究所和麻省理工学院也是这项资助的合作机构。DF/HCC前列腺癌孢子在DFCI有其行政基础。自DF/HCC前列腺癌项目和SPORE成立以来一直领导该项目的Philip Kantoff博士与DFCI的实验室科学家William Hahn博士和BIDMC的实验室科学家Steven Balk博士共同担任董事。Kantoff博士直接向DF/HCC主任兼DFCI总裁Edward Benz博士汇报。DF/HCC前列腺癌孢子拥有广泛而深厚的人才基础，并有广泛的机构承诺。作为DF/HCC的一部分，我们利用了庞大的患者群体和尖端技术。我们提出了4个项目来解决前列腺癌的关键问题，包括：1)了解肥胖影响前列腺癌死亡率的机制；2)剖析gleason7前列腺癌的临床异质性；3)了解基因组变化对原发性雄激素剥夺治疗和侵袭性前列腺癌的耐药性的作用；4)了解基于雄激素受体的前列腺癌耐药机制去势抵抗疾病。这四个项目由三个核心支持：行政核心、生物统计学和计算生物学核心以及组织和病理学核心。我们也有一个非常成功的职业发展计划，选择有才华的内科科学家并指导他们独立，以及一个发展项目计划，为孢子的未来产生新的想法。

This application represents a revised resubmission application for a Specialized Program of Research Excellence (SPORE) in Prostate Cancer from the Prostate Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Prostate Cancer SPORE has been funded for two cycles since 2002. DF/HCC is comprised of the following institutions: Dana-Farber Cancer Institute; Harvard Medical School; Harvard School of Public Health; Beth Israel-Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; and Children's Hospital of Boston. In addition to the institutions in the DF/HCC, the Broad Institute and Massachusetts Institute of Technology are collaborating institutions in this grant. The DF/HCC Prostate Cancer SPORE has its administrative base at the DFCI. Dr. Philip Kantoff, who has led the DF/HCC Prostate Cancer Program and SPORE since their inception, is joined by Co-Directors Dr. William Hahn, a laboratory scientist at DFCI, and Dr. Steven Balk, a laboratory scientist at BIDMC. Dr. Kantoff reports directly to Dr. Edward Benz, Director of DF/HCC and President of DFCI. The DF/HCC Prostate Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 4 Projects which address critical problems in prostate cancer and have translational components including 1) understanding the mechanism by which obesity impacts prostate cancer mortality 2) dissecting the clinical heterogeneity of Gleason 7 prostate cancer 3) understanding the role that genomic change has on resistance to primary androgen deprivation therapy and on aggressive prostate cancer and finally 4) understanding the androgen receptor based mechanisms of resistance in castration resistant disease. The four projects are supported by three Cores - an Administrative Core, a Biostatistics and Computational Biology Core, and a Tissue and Pathology Core. We also have a highly successful Career Development Program that selects talented physician scientists and mentors them to independence as well as a Developmental Projects Program that generates new ideas for the SPORE in the future.